Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.41 |
| ▸ | EGLN3 | Q9H6Z9 | 5/20 | 0.41 |
| ▸ | VEGFA | P15692 | 4/20 | 0.41 |
| ▸ | FLT1 | P17948 | 4/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24257795 | 1.00 | EGLN1 (0.41) | EGLN1EGLN3VEGFAFLT1AKR1C3 | |
| SCHEMBL24257501 | 0.88 | EGLN1 (0.48) | EGLN1EGLN3VEGFAFLT1FTO | |
| SCHEMBL30454632 | 0.88 | EGLN1 (0.48) | EGLN1EGLN3VEGFAFLT1FTO | |
| SCHEMBL30452524 | 0.88 | KDM4E (0.46) | EGLN1EGLN3VEGFAFLT1FTO | |
| SCHEMBL24257788 | 0.88 | KDM4E (0.46) | EGLN1EGLN3VEGFAFLT1FTO | |
| SCHEMBL24257817 | 0.87 | EGLN1 (0.50) | EGLN1EGLN3VEGFAFLT1FTO | |
| SCHEMBL30452725 | 0.87 | EGLN1 (0.50) | EGLN1EGLN3VEGFAFLT1FTO | |
| SCHEMBL24257789 | 0.85 | PPID (0.42) | EGLN1EGLN3VEGFAFLT1FTO | |
| SCHEMBL30452447 | 0.85 | PPID (0.42) | EGLN1EGLN3VEGFAFLT1FTO | |
| SCHEMBL24257704 | 0.84 | PPARG (0.39) | EGLN1EGLN3AKR1C3AKR1C2FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4196466-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | EGLN1 19/4885EGLN3 2/4885VEGFA 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.